Multicentre randomized phase II study with Gemcitabine (GEM) plus cisplatin (CDDP) in patients with stage IIIB-IV NSCLC

被引：0
|
作者：
Ricci, S
Antonuzzo, A
Galli, L
Algeri, R
Bonifazi, V
Andrei, A
Petruzzelli, S
Dupre, C
Pegna, AL
Conte, PF
机构：
[1] Osped S Chiara, Pisa, Italy
[2] Osped Civile Misericordia, Grosseto, Italy
[3] Osped Cisanello, Pisa, Italy
[4] Osped Careggi, Florence, Italy
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
456
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [21] Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study
    Gebbia, V
    Galetta, D
    Riccardi, F
    Gridelli, C
    Durini, E
    Borsellino, N
    Gebbia, N
    Valdesi, M
    Caruso, M
    Valenza, R
    Pezzella, G
    Colucci, G
    LUNG CANCER, 2002, 37 (02) : 179 - 187
  • [22] Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer
    Iaffaioli, RV
    Tortoriello, A
    Facchini, G
    Capenigro, F
    Gentile, M
    Marzano, N
    Gravina, A
    Dimitri, P
    Costagliola, G
    Ferraro, A
    Ferrante, G
    De Marino, V
    Illiano, A
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) : 921 - 926
  • [23] Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer
    Mylonakis, N.
    Athanasiou, A.
    Ziras, N.
    Angel, J.
    Rapti, A.
    Lampaki, S.
    Politis, N.
    Karanikas, C.
    Kosmas, C.
    LUNG CANCER, 2010, 68 (02) : 240 - 247
  • [24] Gemcitabine-epidoxorubicin-cisplatin (GEP) as a new triplet combination chemotherapy in patients with stage IIIB-IV non small cell lung cancer (NSCLC). A dose finding study
    Barni, S
    Pronzato, P
    Cazzaniga, M
    Vigani, A
    Frontini, L
    Di Costanzo, F
    LUNG CANCER, 2005, 49 : S235 - S235
  • [25] Cisplatin (CDDP), Paclitaxel (TAX) and Gemcitabine (GEM) as primary chemotherapy for stage IIIA unresectable/IIIB non-small cell lung cancer (NSCLC)
    Mansueto, Giovanni
    Fariello, Anna Maria
    Cianci, Giovanni
    Magnolfi, Emanuela
    Gamucci, Teresa
    ANNALS OF ONCOLOGY, 2005, 16 : 24 - 24
  • [26] Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer:: a phase III randomized trial
    Zatloukal, P
    Petruzelka, L
    Zemanová, M
    Kolek, V
    Skricková, J
    Pesek, M
    Fojtu, H
    Grygárková, I
    Sixtová, D
    Roubec, J
    Horenková, E
    Havel, L
    Prusa, P
    Nováková, L
    Skácel, T
    Kuta, M
    LUNG CANCER, 2003, 41 (03) : 321 - 331
  • [27] A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus Ifosfamide versus gemcitabine plus cisplatin in the treatment of chemonaive patients with stage III and IV non-small cell lung cancer (NSCLC)
    Teodorescu, G
    Ciuleanu, T
    Grigorescu, A
    Firoiu, E
    Muresan, DR
    LUNG CANCER, 2005, 49 : S271 - S272
  • [28] Gemcitabine plus cisplatin in patients with state IIIB/IV non-small cell lung cancer (NSCLC)
    Teixeira, Encarnacao
    Goncalves, Ines
    Mayor, Renato Sotto
    Melo, Ricardo
    Lopes, Carlos
    Pinto, Ana
    ANNALS OF ONCOLOGY, 2004, 15 : 194 - 194
  • [29] A PLASMA PROTEOMIC SIGNATURE PREDICTS OUTCOMES IN A PHASE 3 STUDY OF GEMCITABINE (G) plus CISPLATIN (C) ± SORAFENIB IN FIRST LINE STAGE IIIB OR IV NSCLC
    Vansteenkiste, J. F.
    Paz-Ares, L.
    Eisen, T. Q. G.
    Heigener, D.
    Eberhardt, W.
    Thomas, M.
    Zhou, C.
    Santoro, A.
    Lathia, C.
    Roder, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 407 - 407
  • [30] Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
    Reinmuth, N.
    Meyer, A.
    Hartwigsen, D.
    Schaeper, C.
    Huebner, G.
    Skock-Lober, R.
    Bier, A.
    Gerecke, U.
    Held, C. -P.
    Reck, M.
    LUNG CANCER, 2014, 83 (03) : 363 - 368
12345